‘‘(i) PURPOSES.—The Northern Border 
Counternarcotics Strategy shall— 
‘‘(I) set forth the strategy of the 
Federal Government for preventing the 
illegal trafficking of drugs across the 
international 
border 
between 
the 
United States and Canada, including 
through ports of entry and between 
ports of entry on the border; 
‘‘(II) state the specific roles and 
responsibilities of each relevant Na-
tional Drug Control Program Agency 
for implementing the strategy; 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National Drug Control Program Agen-
cies to implement the strategy; 
‘‘(IV) be designed to promote, and 
not hinder, legitimate trade and travel; 
and 
‘‘(V) reflect the unique nature of 
small communities along the inter-
national border between the United 
States and Canada, ongoing coopera-
tion and coordination with Canadian 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
law, enforcement authorities, and vari-
ations in the volumes of vehicles and 
pedestrians crossing through ports of 
entry along the international border 
between the United States and Canada. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
CROSS-BORDER
INDIAN
RESERVATIONS.— 
The 
Northern 
Border 
Counternarcotics 
Strategy shall include— 
‘‘(I) a strategy to end the illegal 
trafficking of drugs to or through In-
dian reservations on or near the inter-
national border between the United 
States and Canada; and 
‘‘(II) recommendations for addi-
tional assistance, if any, needed by 
Tribal law enforcement agencies relat-
ing to the strategy, including an eval-
uation of Federal technical and finan-
cial assistance, infrastructure capacity 
building, and interoperability defi-
ciencies. 
‘‘(3) CLASSIFIED
INFORMATION.—Any contents 
of the National Drug Control Strategy that involve 
information properly classified under criteria estab-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
lished by an Executive order shall be presented to 
Congress separately from the rest of the National 
Drug Control Strategy. 
‘‘(4) SELECTION OF DATA AND INFORMATION.— 
In selecting data and information for inclusion under 
paragraph (1), the Director shall ensure— 
‘‘(A) the inclusion of data and information 
that will permit analysis of current trends 
against previously compiled data and informa-
tion where the Director believes such analysis en-
hances long-term assessment of the National 
Drug Control Strategy; and 
‘‘(B) the inclusion of data and information 
to permit a standardized and uniform assess-
ment of the effectiveness of drug treatment pro-
grams in the United States. 
‘‘(d) ANNUAL PERFORMANCE SUPPLEMENT.—Not later 
than the first Monday in February of each year following 
the year in which the National Drug Control Strategy is 
submitted pursuant to subsection (a)(2), the Director shall 
submit to the appropriate congressional committees a sup-
plement to the Strategy that shall include— 
‘‘(1) annual and quarterly quantifiable and 
measurable objectives and specific targets to accom-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
plish long-term quantifiable goals specified in the 
Strategy; and 
‘‘(2) for each year covered by the Strategy, a per-
formance evaluation plan for each goal listed in the 
Strategy for each National Drug Control Program 
Agency, including— 
‘‘(A) specific performance measures for each 
National Drug Control Program Agency and 
each such agency’s related programs and activi-
ties; 
‘‘(B) annual and quarterly objectives and 
targets for each performance measure; and 
‘‘(C) an estimate of Federal funding and 
other resources needed to achieve each perform-
ance measure. 
‘‘(e) SUBMISSION OF REVISED STRATEGY.—The Presi-
dent may submit to Congress a revised National Drug Con-
trol Strategy that meets the requirements of this section— 
‘‘(1) at any time, upon a determination of the 
President, in consultation with the Director, that the 
National Drug Control Strategy in effect is not suffi-
ciently effective; or 
‘‘(2) if a new President or Director takes office. 
‘‘(f) FAILURE OF PRESIDENT TO SUBMIT NATIONAL 
DRUG CONTROL STRATEGY.—If the President does not sub-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
mit a National Drug Control Strategy to Congress in ac-
cordance with subsection (a)(2), not later than five days 
after the first Monday in February following the year in 
which the term of the President commences, the President 
shall send a notification to the appropriate congressional 
committees— 
‘‘(1) explaining why the Strategy was not sub-
mitted; and 
‘‘(2) specifying the date by which the Strategy 
will be submitted. 
‘‘§ 1006. Development of an annual national drug con-
trol assessment 
‘‘(a) TIMING.—Not later than the first Monday in Feb-
ruary of each year, the Director shall submit to the Presi-
dent, Congress, and the appropriate congressional commit-
tees, a report assessing the progress of each National Drug 
Control Program Agency toward achieving the annual 
goals, objectives, and targets contained in the National 
Drug Control Strategy applicable to the prior fiscal year. 
‘‘(b) PROCESS FOR DEVELOPMENT OF THE ANNUAL 
ASSESSMENT.—Not later than November 1 of each year, the 
head of each National Drug Control Program Agency shall 
submit, in accordance with guidance issued by the Director, 
to the Director an evaluation of progress by the agency with 
respect to drug control program goals using the performance 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
measures for the agency developed under this section, in-
cluding progress with respect to— 
‘‘(1) success in achieving the goals of the Na-
tional Drug Control Strategy; 
‘‘(2) success in reducing domestic and foreign 
sources of illegal drugs; 
‘‘(3) success in expanding access to and increas-
ing the effectiveness of substance use disorder treat-
ment; 
‘‘(4) success in protecting the borders of the 
United States (and in particular the Southwestern 
border of the United States) from penetration by ille-
gal narcotics; 
‘‘(5) success in reducing crime associated with 
drug use in the United States; 
‘‘(6) success in reducing the negative health and 
social consequences of drug use in the United States; 
and 
‘‘(7) implementation of drug treatment and pre-
vention programs in the United States and improve-
ments in the adequacy and effectiveness of such pro-
grams. 
‘‘(c) CONTENTS OF THE ANNUAL ASSESSMENT.—The 
Director shall include in the annual assessment required 
under subsection (a)— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
mation submitted to the Director under section 
1007(b); 
‘‘(6) an assessment of the effectiveness of any 
Emerging Threat Response Plan in effect for the pre-
vious year, including a specific evaluation of whether 
the objectives and targets were met and reasons for the 
success or failure of the previous year’s plan; 
‘‘(7) a detailed accounting of the amount of 
funds obligated during the previous fiscal year for 
carrying out the media campaign under section 
1009(d), including each recipient of funds, the pur-
pose of each expenditure, the amount of each expendi-
ture, any available outcome information, and any 
other information necessary to provide a complete ac-
counting of the funds expended; and 
‘‘(8) the assessments required under this sub-
section shall be based on the Performance Measure-
ment System describe in subsection (d). 
‘‘(d) PERFORMANCE MEASUREMENT SYSTEM.—The 
Director shall include in the annual assessment required 
under subsection (a) a national drug control performance 
measurement system, that— 
‘‘(1) develops annual, 2-year, and 5-year per-
formance measures, objectives, and targets for each 
National Drug Control Strategy goal and objective es-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00045
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
tablished for reducing drug use, availability, and the 
consequences of drug use; 
‘‘(2) describes the sources of information and 
data that will be used for each performance measure 
incorporated into the performance measurement sys-
tem; 
‘‘(3) identifies major programs and activities of 
the National Drug Control Program Agencies that 
support the goals and annual objectives of the Na-
tional Drug Control Strategy; 
‘‘(4) evaluates the contribution of demand reduc-
tion and supply reduction activities implemented by 
each National Drug Control Program Agency in sup-
port of the National Drug Control Strategy; 
‘‘(5) monitors consistency between the drug-re-
lated goals, measures, targets, and objectives of the 
National Drug Control Program Agencies and ensures 
that each agency’s goals and budgets support, and are 
fully consistent with, the National Drug Control 
Strategy; and 
‘‘(6) coordinates the development and implemen-
tation of national drug control data collection and re-
porting systems to support policy formulation and 
performance measurement, including an assessment 
of— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00046
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) the quality of current drug use meas-
urement instruments and techniques to measure 
supply reduction and demand reduction activi-
ties; 
‘‘(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments 
and techniques to measure the illicit drug user 
population, and groups that are at risk for illicit 
drug use; 
‘‘(C) the adequacy of the coverage of existing 
national treatment outcome monitoring systems 
to measure the effectiveness of substance use dis-
order treatment in reducing illicit drug use and 
criminal behavior during and after the comple-
tion of substance use disorder treatment; and 
‘‘(D) the actions the Director shall take to 
correct any deficiencies and limitations identi-
fied pursuant to subparagraphs (A), (B), and 
(C). 
‘‘(e) MODIFICATIONS.—A description of any modifica-
tions made during the preceding year to the national drug 
performance measurement system described in subsection 
(d) shall be included in each report submitted under sub-
section (a). 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00047
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(f) ANNUAL REPORT ON CONSULTATION.—The Direc-
tor shall include in the annual assessment required under 
subsection (a)— 
‘‘(1) a detailed description of how the Office has 
consulted with and assisted State, local, and Tribal 
governments with respect to the formulation and im-
plementation of the National Drug Control Strategy 
and other relevant issues; and 
‘‘(2) a general review of the status of, and trends 
in, demand reduction activities by private sector enti-
ties and community-based organizations, including 
faith-based organizations, to determine their effective-
ness and the extent of cooperation, coordination, and 
mutual support between such entities and organiza-
tions and Federal, State, local, and Tribal govern-
ment agencies. 
‘‘(g) PERFORMANCE-BUDGET COORDINATOR.— 
‘‘(1) DESIGNATION.—The Director shall des-
ignate or appoint a United States Performance-Budg-
et Coordinator to— 
‘‘(A) ensure the Director has sufficient in-
formation about the performance of each Na-
tional Drug Control Program Agency, the im-
pact Federal funding has had on the goals in the 
Strategy, and the likely contributions to the 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00048
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
goals of the Strategy based on funding levels of 
each National Drug Control Program Agency, to 
make an independent assessment of the budget 
request of each agency under section 1004; 
‘‘(B) advise the Director on agency budgets, 
performance measures and targets, and addi-
tional data and research needed to make in-
formed policy decisions in the National Drug 
Control Budget and Strategy; and 
‘‘(C) other duties as may be determined by 
the Director with respect to measuring or assess-
ing performance or agency budgets. 
‘‘(2) DETERMINATION OF POSITION.—The Direc-
tor shall determine whether the coordinator position 
is a career or noncareer position in the Senior Execu-
tive Service. 
‘‘§ 1007. Monitoring and evaluation of national drug 
control program 
‘‘(a) IN GENERAL.—The Director shall monitor imple-
mentation of the National Drug Control Program and the 
activities of the National Drug Control Program Agencies 
in carrying out the goals and objectives of the National 
Drug Control Strategy including— 
‘‘(1) conducting program and performance au-
dits and evaluations; and 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00049
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(2) requesting assistance from the Inspector 
General of the relevant agency in such audits and 
evaluations. 
‘‘(b) ACCOUNTING OF FUNDS EXPENDED.—Not later 
than December 1 of each year and in accordance with guid-
ance issued by the Director, the head of each National Drug 
Control Program Agency shall submit to the Director a de-
tailed accounting of all funds expended by the agency for 
National Drug Control Program activities during the pre-
vious fiscal year and shall ensure such detailed accounting 
is authenticated by the Inspector General for such agency 
prior to submission to the Director. 
‘‘(c) NOTIFICATION.—The Director shall notify any 
National Drug Control Program Agency if its activities are 
not in compliance with the responsibilities of the agency 
under the National Drug Control Strategy, transmit a copy 
of each such notification to the President and the appro-
priate congressional committees, and maintain a copy of 
each such notification. 
‘‘(d) RECOMMENDATIONS.—The Director shall make 
such recommendations to the President and the appropriate 
congressional committees as the Director determines are ap-
propriate regarding changes in the organization, manage-
ment, and budgets of the National Drug Control Program 
Agencies, and changes in the allocation of personnel to and 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00050
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
within those agencies, to implement the policies, goals, pri-
orities, and objectives established under section 1002(c)(1) 
and the National Drug Control Strategy. 
‘‘(e) AUTHORIZATION, DEVELOPMENT, AND IMPLEMEN-
TATION OF A COORDINATED TRACKING SYSTEM.— 
‘‘(1) ESTABLISHMENT.—The Director, shall es-
tablish a coordinated tracking system of federally- 
funded initiatives and grant programs which shall— 
‘‘(A) be the central repository of all relevant 
grants; 
‘‘(B) identify duplication, overlap, or gaps 
in funding to provide increased accountability of 
federally-funded grants for substance abuse treat-
ment, prevention, and enforcement; 
‘‘(C) identify impediments that applicants 
currently have in the grant application process 
with applicable agencies; and 
‘‘(D) be developed and maintained by the 
Office with the support of designated National 
Drug Control Program Agencies, and any other 
agency determined by the Director. 
‘‘(2) PERFORMANCE
METRICS.—The Director 
shall identify metrics and achievable goals for grant 
recipients in furtherance of the Strategy. Such 
metrics should be used to measure how effective each 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00051
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
federally funded initiative is in achieving the objec-
tives of the Strategy and to enable comparisons of fed-
erally funded initiatives to identify those that are the 
most cost effective. 
‘‘(3) GRANT APPLICATION STANDARDIZATION.— 
The Director, in consultation with the head of each 
National Drug Control Program Agency, shall develop 
a plan for coordinating and standardizing drug con-
trol grant application processes and develop a joint 
application to be used by all National Drug Control 
Program Agencies to reduce the administrative bur-
den and improve oversight of Federal funds. 
‘‘(4) CENTRAL
PORTAL.—The Director shall 
maintain on the public, electronic portal of the Office 
a list all drug control grant award opportunities 
available in a central location. The head of each Na-
tional Drug Control Program Agency shall provide a 
complete list of all drug control program grant award 
opportunities to the Director and annually update 
such list. 
‘‘(5) REPORT TO CONGRESS.—The Director shall 
include in the assessment submitted to Congress under 
section 1006 an assessment on progress under this sec-
tion and the feasibility of block grants of Federal 
funding to States. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00052
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘§ 1008. Coordination and oversight of the national 
drug control program 
‘‘(a) IN GENERAL.—The Director shall coordinate and 
oversee the implementation by the National Drug Control 
Program Agencies of the policies, goals, objectives, and pri-
orities established under section 1002(c)(1) and the fulfill-
ment of the responsibilities of such agencies under the Na-
tional Drug Control Strategy and make recommendations 
to National Drug Control Program Agency heads with re-
spect to implementation of National Drug Control Pro-
grams. 
‘‘(b) DETAILING EMPLOYEES TO OTHER AGENCIES.— 
‘‘(1) REQUEST.—The Director may request the 
head of an agency or program of the Federal Govern-
ment to place agency personnel who are engaged in 
drug control activities on temporary detail to another 
agency in order to implement the National Drug Con-
trol Strategy. 
‘‘(2) AGENCY
COMPLIANCE.—The head of the 
agency shall comply with such a request. 
‘‘(3) MAXIMUM
NUMBER
OF
DETAILEES.—The 
maximum number of personnel who may be detailed 
to another agency (including the Office) under this 
subsection during any fiscal year is— 
‘‘(A) for the Department of Defense, 50; and 
‘‘(B) for any other agency, 10. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00053
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(c) DIRECTING FEDERAL FUNDING.—The Director 
may transfer funds made available to a National Drug 
Control Program Agency for National Drug Control Strat-
egy programs and activities to another account within such 
agency or to another National Drug Control Program Agen-
cy for National Drug Control Strategy programs and ac-
tivities, except that— 
‘‘(1) the authority under this subsection may be 
limited in an annual appropriations Act or other 
provision of Federal law; 
‘‘(2) the Director may exercise the authority 
under this subsection only with the concurrence of the 
head of each affected agency; 
‘‘(3) in the case of an interagency transfer, the 
total amount of transfers under this subsection may 
not exceed 3 percent of the total amount of funds 
made available for National Drug Control Strategy 
programs and activities to the agency from which 
those funds are to be transferred; 
‘‘(4) funds transferred to an agency under this 
subsection may only be used to increase the funding 
for programs or activities authorized by law; 
‘‘(5) the Director shall— 
‘‘(A) submit to the appropriate congres-
sional committees and any other applicable com-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00054
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
mittees of jurisdiction, a reprogramming or 
transfer request in advance of any transfer under 
this subsection in accordance with the regula-
tions of the affected agency or agencies; and 
‘‘(B) annually submit to the appropriate 
congressional committees a report describing the 
effect of all transfers of funds made pursuant to 
this subsection or section 1004(f) during the 12- 
month period preceding the date on which the re-
port is submitted; and 
‘‘(6) funds may only be used for— 
‘‘(A) expansion of demand reduction activi-
ties; 
‘‘(B) interdiction of illicit drugs on the high 
seas, in United States territorial waters, and at 
United States ports of entry by officers and em-
ployees of Drug Control Program Agencies and 
domestic and foreign law enforcement officers; 
‘‘(C) accurate assessment and monitoring of 
international drug production and interdiction 
programs and policies; 
‘‘(D) activities to facilitate and enhance the 
sharing of domestic and foreign intelligence in-
formation among Drug Control Program Agen-
cies related to the production and trafficking of 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00055
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
drugs in the United States and foreign countries; 
and 
‘‘(E) activities to prevent the diversion of 
prescription drugs for illicit use and research re-
lated to any of these activities. 
‘‘(d) DIRECTING FEDERAL FUNDING TO RESPOND TO 
EMERGING THREATS.— 
‘‘(1) IN GENERAL.—The Director may transfer 
funds made available to a National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to another account within 
such agency or to another National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to implement the provisions 
of a plan developed under section 1009, except that— 
‘‘(A) the authority under this subsection 
may be limited in an annual appropriations Act 
or other provision of Federal law; 
‘‘(B) in the case of an interagency transfer, 
the total amount of transfers under this sub-
section may not exceed 10 percent of the total 
amount of funds made available for National 
Drug Control Strategy programs and activities 
to the agency from which those funds are to be 
transferred; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00056
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(C) funds transferred to an agency under 
this subsection may only be used to increase the 
funding for programs or activities authorized by 
law; 
‘‘(D) no transfer of funds under this sub-
section may result in a reduction in total Fed-
eral expenditures for substance use disorder 
treatment; 
‘‘(E) the Director shall— 
‘‘(i) submit to the appropriate congres-
sional committees and any other applicable 
committees of jurisdiction, a reprogram-
ming or transfer request in advance of any 
transfer under this subsection in accordance 
with the regulations of each affected agency; 
and 
‘‘(ii) annually submit to the appro-
priate congressional committees a report de-
scribing the effect of all transfers of funds 
made pursuant to this subsection or section 
1004(f) during the 12-month period pre-
ceding the date on which the report is sub-
mitted; and 
‘‘(F) funds may only be used for— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00057
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(i) expansion of demand reduction ac-
tivities; 
‘‘(ii) interdiction of illicit drugs on the 
high seas, in United States territorial 
waters, and at United States ports of entry 
by officers and employees of Drug Control 
Program agencies and domestic and foreign 
law enforcement officers; 
‘‘(iii) accurate assessment and moni-
toring of international drug production and 
interdiction programs and policies; 
‘‘(iv) activities to facilitate and en-
hance the sharing of domestic and foreign 
intelligence information among Drug Con-
trol Program Agencies related to the pro-
duction and trafficking of drugs in the 
United States and foreign countries; and 
‘‘(v) activities to prevent the diversion 
of prescription drugs for illicit use and re-
search related to any of these activities. 
‘‘(2) INADEQUACY OF TRANSFER.—In the event 
the authority under this subsection is inadequate to 
implement the provisions of a plan developed under 
section 1009, the Director shall submit a request for 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00058
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
funding to Congress as soon as the Director becomes 
aware of the need for additional funding. 
‘‘(e) FUND CONTROL NOTICES.— 
‘‘(1) IN GENERAL.—The Director may issue to 
the head of a National Drug Control Program Agency 
a fund control notice to ensure compliance with the 
National Drug Control Program Strategy. A fund 
control notice may direct that all or part of an 
amount appropriated to the National Drug Control 
Program Agency account be obligated by— 
‘‘(A) months, fiscal year quarters, or other 
time periods; and 
‘‘(B) activities, functions, projects, or object 
classes. 
‘‘(2) UNAUTHORIZED OBLIGATION OR EXPENDI-
TURE PROHIBITED.—An officer or employee of a Na-
tional Drug Control Program Agency shall not make 
or authorize an expenditure or obligation contrary to 
a fund control notice issued by the Director. 
‘‘(3) DISCIPLINARY ACTION FOR VIOLATION.—In 
the case of a violation of paragraph (2) by an officer 
or employee of a National Drug Control Program 
Agency, the head of the agency, upon the request of 
and in consultation with the Director, may subject 
the officer or employee to appropriate administrative 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00059
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
discipline, including, when circumstances warrant, 
suspension from duty without pay or removal from 
office. 
‘‘(4) CONGRESSIONAL NOTICE.—Not later than 5 
days after issuance of a fund control notice, the Di-
rector shall submit a copy of such fund control notice 
to the appropriate congressional committees and make 
such notice publicly available. 
‘‘(5) RESTRICTIONS.—The Director shall not 
issue a fund control notice to direct that all or part 
of an amount appropriated to the National Drug 
Control Program Agency account be obligated, modi-
fied, or altered in any manner contrary, in whole or 
in part, to a specific appropriation or statute. 
‘‘(f) EXCLUSIONS.—The authorities described under 
subsections (c), (d), and (e) do not apply to any program 
under subchapter II or III. 
‘‘(g) FOREIGN ASSISTANCE ACT PARTICIPATION.—The 
Director may participate in the drug certification process 
pursuant to section 490 of the Foreign Assistance Act of 
1961 (22 U.S.C. 2291j) and section 706 of the Department 
of State Authorization Act for Fiscal Year 2003 (22 U.S.C. 
229j–l). 
‘‘(h) CERTIFICATIONS OF POLICY CHANGES TO DIREC-
TOR.— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00060
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(1) IN GENERAL.—Subject to paragraph (2), the 
head of a National Drug Control Program Agency 
shall, unless exigent circumstances require otherwise, 
notify the Director in writing regarding any proposed 
change in policies relating to the activities of that 
agency under the National Drug Control Program 
prior to implementation of such change. The Director 
shall promptly review such proposed change and cer-
tify to the head of that agency in writing whether 
such change is consistent with the National Drug 
Control Strategy. 
‘‘(2) EXCEPTION.—If prior notice of a proposed 
change under paragraph (1) is not practicable— 
‘‘(A) the head of the National Drug Control 
Program Agency shall notify the Director of the 
proposed change as soon as practicable; and 
‘‘(B) upon such notification, the Director 
shall review the change and certify to the head 
of that agency in writing whether the change is 
consistent with the National Drug Control Strat-
egy. 
‘‘(i) WORK IN CONJUNCTION WITH ASSISTANT FOR 
NATIONAL SECURITY AFFAIRS.—The Director shall, in any 
matter affecting national security interests, work in con-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00061
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
junction with the Assistant to the President for National 
Security Affairs. 
‘‘§ 1009. Emerging threats taskforce, plan, media cam-
paign 
‘‘(a) EMERGING THREATS TASK FORCE.— 
‘‘(1) EMERGING AND CONTINUING THREATS CO-
ORDINATOR.—The Director shall designate or appoint 
a United States Emerging and Continuing Threats 
Coordinator to perform the duties of that position de-
scribed in this section and such other duties as may 
be determined by the Director. The Director shall de-
termine whether the coordinator position is a career 
or noncareer position in the Senior Executive Service. 
‘‘(2) ESTABLISHMENT
AND
MONITORING.—The 
Emerging and Continuing Threats Coordinator (re-
ferred to in this section as the ‘Coordinator’) shall 
monitor evolving and emerging drug threats in the 
United States and shall serve as Chair of an Emerg-
ing Threats Task Force (in this section, referred to as 
the ‘task force’). The Director shall appoint other 
members of the Task force, which shall include rep-
resentatives from— 
‘‘(A) National Drug Control Program Agen-
cies or other agencies; 
‘‘(B) State, local, and Tribal governments; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00062
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(C) the Director of the Fusion Center es-
tablished in section 1013; and 
‘‘(D) other entities as determined to be nec-
essary by the Director. 
‘‘(3) INFORMATION REVIEW AND SHARING.— 
‘‘(A) IN GENERAL.—The task force shall dis-
seminate and facilitate the sharing with Federal, 
State, local, and Tribal officials and other enti-
ties as determined by the Director of pertinent 
information and data relating to the following: 
‘‘(i) Recent trends in drug supply and 
demand. 
‘‘(ii) Fatal and nonfatal overdoses. 
‘‘(iii) Demand for and availability of 
evidence-based substance use disorder treat-
ment, including the extent of the unmet 
treatment need, and treatment admission 
trends. 
‘‘(iv) Recent trends in drug interdic-
tion, supply, and demand from State, local, 
and Tribal law enforcement agencies. 
‘‘(v) Other subject matter as deter-
mined necessary by the Director. 
‘‘(B) CONTRACT, AGREEMENT, AND OTHER 
AUTHORITY.—The Director may award con-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00063
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
tracts, enter into interagency agreements, man-
age individual projects, and conduct other oper-
ational activities in support of the identification 
of emerging threats and in support of the devel-
opment, implementation, and assessment of 
Emerging Threat Response Plans. 
‘‘(C) DATA ANALYSIS ACTIVITIES.—In sup-
port of the task force, the National Drug Control 
Fusion Center is authorized to conduct and pro-
vide to the task force the results of data analysis 
activities that the task force requests to aid in 
their review of recent trends in the data dissemi-
nated under subparagraph (A). 
‘‘(4) CRITERIA
TO
IDENTIFY
EMERGING
DRUG 
THREATS.—Not later than 60 days after the date on 
which a task force first meets, the task force shall de-
velop and recommend to the Director criteria to be 
used to identify an emerging drug threat or the termi-
nation of an emerging drug threat designation based 
on information gathered by the task force in para-
graph (2), statistical data, and other evidence. 
‘‘(5) MEETINGS.—The task force shall meet in 
person not less frequently than quarterly and at addi-
tional meetings if determined to be necessary by and 
at the call of the Chair to— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00064
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) identify and discuss evolving and 
emerging drug trends in the United States using 
the criteria established in paragraph (3); 
‘‘(B) formulate the plan described in sub-
section (c); 
‘‘(C) oversee implementation of the plan de-
scribed in subsection (c); and 
‘‘(D) provide such other advice to the Coor-
dinator and Director concerning strategy and 
policies for emerging drug threats and trends as 
the task force determines to be appropriate. 
‘‘(b) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consultation 
with the Coordinator, the task force, and the head of 
each National Drug Control Program Agency, may 
designate an emerging drug threat in the United 
States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Direc-
tor, in consultation with the Coordinator, shall pro-
mulgate and make publicly available standards by 
which a designation under paragraph (1) and the ter-
mination of such designation may be made. In devel-
oping such standards, the Director shall consider the 
recommendations of the task force and other criteria 
the Director considers to be appropriate. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00065
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di-
rector shall publish a public written statement on the 
portal of the Office explaining the designation of an 
emerging drug threat or the termination of such des-
ignation and shall notify the appropriate congres-
sional committees of the availability of such statement 
when a designation or termination of such designa-
tion has been made. 
‘‘(c) PLAN.— 
‘‘(1) PUBLIC AVAILABILITY OF PLAN.—Not later 
than 60 days after making a designation under sub-
section (b), the Director shall publish and make pub-
licly available an Emerging Threat Response Plan 
and notify the President and the appropriate congres-
sional committees of such plan’s availability. 
‘‘(2) TIMING.—Not less frequently than every 90 
days after the date on which the plan is published 
under paragraph (1), the Director shall update the 
plan and report on implementation of the plan, until 
the Director issues the public statement required 
under subsection (b)(3) to terminate the emerging 
threat designation. 
‘‘(3) CONTENTS OF AN EMERGING THREAT RE-
SPONSE
PLAN.—The Director shall include in the 
plan— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00066
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) a comprehensive strategic assessment 
of the emerging drug threat, including the cur-
rent availability of, demand for, and effectiveness 
of evidence-based prevention, treatment, and en-
forcement programs and efforts to respond to the 
emerging drug threat; 
‘‘(B) comprehensive, research-based, long- 
range, quantifiable goals for addressing the 
emerging drug threat, including for reducing the 
supply of the emerging drug threat and for ex-
panding the availability and effectiveness of evi-
dence-based substance use disorder treatment and 
prevention programs to reduce the demand for 
the emerging drug threat; 
‘‘(C) performance measures pertaining to 
the plan’s goals, including quantifiable and 
measurable objectives and specific targets; 
‘‘(D) the level of funding needed to imple-
ment the plan, including whether funding is 
available to be reprogrammed or transferred to 
support implementation of the plan or whether 
additional appropriations are necessary to im-
plement the plan; 
‘‘(E) an implementation strategy for the 
education and public awareness campaign under 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00067
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
subsection (d), including goals as described 
under subparagraph (B) and performance meas-
ures, objectives, and targets, as described under 
subparagraph (C); and 
‘‘(F) any other information necessary to in-
form the public of the status, progress, or re-
sponse of an emerging drug threat. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN GENERAL.—Not later than 90 days 
after the date on which a designation is made 
under subsection (b), the Director, in consulta-
tion with the President, the appropriate congres-
sional committees, and the head of each National 
Drug Control Program Agency, shall issue guid-
ance on implementation of the plan described in 
subsection (c) to the National Drug Control Pro-
gram Agencies and any other relevant agency de-
termined to be necessary by the Director. 
‘‘(B) COORDINATOR’S RESPONSIBILITIES.— 
The Coordinator shall— 
‘‘(i) direct the implementation of the 
plan among the agencies identified in the 
plan, State, local, and Tribal governments, 
and other relevant entities; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00068
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(ii) facilitate information-sharing be-
tween agencies identified in the plan, State, 
local, and Tribal governments, and other 
relevant entities; and 
‘‘(iii) monitor implementation of the 
plan by coordinating the development and 
implementation of collection and reporting 
systems to support performance measure-
ment and adherence to the plan by agencies 
identified in plan, where appropriate. 
‘‘(C) REPORTING.—Not later than 180 days 
after designation under subsection (b) and in ac-
cordance with paragraph (2)(C), the head of each 
agency identified in the plan shall submit to the 
Coordinator a report on implementation of the 
plan. 
‘‘(d) EDUCATION AND PUBLIC AWARENESS CAMPAIGN 
FOR EMERGING DRUG THREATS.— 
‘‘(1) IN GENERAL.—Not later than 90 days after 
a designation under subsection (b), the Director shall 
establish and implement an evidence-based substance 
use prevention education and public awareness cam-
paign to inform the public about the dangers of any 
drug designated as an emerging drug threat. Such 
campaign shall— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00069
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) educate the public about the dangers of 
such drug, including patient and family edu-
cation about the characteristics and hazards of 
such drugs and methods to safeguard against 
such dangers, including the safe disposal of such 
drugs; 
‘‘(B) support evidence-based prevention pro-
grams targeting audiences’ attitudes, percep-
tions, and beliefs concerning substance use and 
intentions to initiate or continue such use; 
‘‘(C) increase awareness of the negative con-
sequences of drug use; 
‘‘(D) encourage individuals affected by sub-
stance use disorders to seek treatment and pro-
vide such individuals with information on how 
to recognize addiction issues, what forms of evi-
dence-based treatment options are available, and 
how to access such treatment; and 
‘‘(E) combat the stigma of addiction and 
substance use disorders, including the stigma of 
treating such disorders with medication-assisted 
treatment therapies. 
‘‘(2) CONSULTATION.—For the planning of the 
campaign under paragraph (1), the Secretary shall 
consult with— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00070
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) the head of any appropriate National 
Drug Control Program Agency to obtain advice 
on evidence-based scientific information for pol-
icy, program development, and evaluation; 
‘‘(B) experts in evidence-based media cam-
paigns, education, evaluation, and communica-
tion; 
‘‘(C) experts on the designated drug; 
‘‘(D) State, local, and Tribal government of-
ficials and relevant agencies; 
‘‘(E) the public; 
‘‘(F) appropriate congressional committees; 
and 
‘‘(G) any other affected person. 
‘‘(3) GIFTS AND DONATIONS.— 
‘‘(A) IN GENERAL.—The Director may ac-
cept gifts and donations (in cash or in kind, in-
cluding voluntary and uncompensated services or 
property), which shall be available until ex-
pended, for the purpose of supporting the edu-
cation and outreach campaign authorized in this 
section, including the media campaign. 
‘‘(B) ETHICS
GUIDELINES.—The Director 
shall establish written guidelines setting forth the 
criteria to be used in determining whether a gift 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00071
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
or donation should be declined under this section 
because the acceptance of the gift or donation 
would— 
‘‘(i) reflect unfavorably upon the abil-
ity of the Director or the Office, or any em-
ployee of the Office, to carry out responsibil-
ities or official duties under this chapter in 
a fair and objective manner; or 
‘‘(ii) compromise the integrity or the 
appearance of integrity of programs or serv-
ices provided under this chapter or of any 
official involved in those programs or serv-
ices. 
‘‘(C) ANNUAL
REPORT
REQUIRED.—Not 
later than the first Monday in the February of 
each year, the Director shall submit to the ap-
propriate congressional committees an annual 
report that identifies the sources of any gift or 
donation accepted by the Office or any con-
tractor acting on behalf of the Office, under this 
subsection, including the value of each gift and 
donation provided by each source of the gift. 
‘‘(4) IMPLEMENTATION.— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00072
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) IN GENERAL.—For any campaign es-
tablished under this subsection, the Director shall 
ensure the following: 
‘‘(i) Implementation is evidence-based, 
meets accepted standards for public aware-
ness campaigns, and uses available re-
sources in a manner to make the most 
progress toward achieving the goals identi-
fied in the emerging threats plan and para-
graph (1). 
‘‘(ii) Information disseminated through 
the campaign is accurate. 
‘‘(iii) The Director approves the strat-
egy of the campaign, all material distrib-
uted through the campaign, and the use of 
any Federal funds used for the campaign. 
‘‘(iv) The campaign is designed using 
strategies found to be most effective at 
achieving such goals, which may include— 
‘‘(I) a media campaign, as de-
scribed in subparagraph (B); 
‘‘(II) local, regional, or popu-
lation specific messaging; 
‘‘(III) establishing partnerships 
and promoting coordination among 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00073
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
community 
stakeholders, 
including 
public, nonprofit organizations, and 
for profit entities; 
‘‘(IV) providing support, training, 
and technical assistance to establish 
and expand school and community 
prevention programs; 
‘‘(V) creating websites to publicize 
and disseminate information; 
‘‘(VI) conducting outreach and 
providing educational resources for 
parents; 
‘‘(VII) establishing State or re-
gional advisory councils to provide 
input and recommendations to raise 
awareness regarding the drug des-
ignated as an emerging drug threat; 
‘‘(VIII) collaborating with law en-
forcement; and 
‘‘(IX) support for school-based 
public health education classes to im-
prove teen knowledge about the effects 
of such designated drug. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00074
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(B) MEDIA
CAMPAIGN.—Any campaign 
implemented under this subsection may include 
a media component, which— 
‘‘(i) shall be designed to prevent the use 
of the drug designated as an emerging drug 
threat and to achieve the goals of paragraph 
(1); 
‘‘(ii) shall be carried out through com-
petitively awarded contracts to entities pro-
viding for the professional production and 
design of such campaign; and 
‘‘(iii) may include the use of television, 
radio, Internet, social media, and other 
commercial marketing venues and may be 
targeted to specific age groups based on 
peer-reviewed social research. 
‘‘(C) REQUIRED NOTICE FOR COMMUNICA-
TION FROM THE OFFICE.—Any communication, 
including an advertisement, paid for or other-
wise disseminated by the Office directly or 
through a contract awarded by the Office shall 
include a prominent notice informing the audi-
ence that the communication was a paid for by 
of the Office. 
‘‘(5) EVALUATION.— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00075
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) PERFORMANCE EVALUATION.—The Di-
rector shall include an evaluation of the cam-
paign in the annual assessment under section 
1006, which shall include the following: 
‘‘(i) A performance evaluation of the 
campaign, including progress toward meet-
ing the goals, objectives, measures, and tar-
gets identified in the emerging threats plan. 
‘‘(ii) A description of all policies and 
practices to eliminate the potential for 
waste, fraud, abuse, and to ensure Federal 
funds are used responsibly. 
‘‘(iii) A list of all contracts or other 
agreements entered into to implement the 
campaign. 
‘‘(iv) The results of any financial audit 
of the campaign. 
‘‘(v) A description of any evidence used 
to develop the campaign. 
‘‘(B) 
INDEPENDENT
EVALUATION.—Not 
later than 180 days after establishing a cam-
paign under paragraph (1) and not less than 
frequently than every two years thereafter, the 
Director shall— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(i) designate an independent entity to 
evaluate the effectiveness of the campaign 
with meeting the goals established in the 
emerging threat plan and paragraph (1); 
and 
‘‘(ii) submit the results of the inde-
pendent evaluation to the appropriate con-
gressional committees. 
‘‘(6) FUNDING
PROHIBITIONS.—None of the 
amounts made available under this subsection may be 
obligated for any of the following: 
‘‘(A) To supplant current anti-drug commu-
nity-based coalitions. 
‘‘(B) To supplant pro bono public service 
time donated by national and local broadcasting 
network for other public services campaigns. 
‘‘(C) For partisan political purposes, or ex-
press advocacy in support of or to defeat any 
clearly identified candidate, clearly identified 
ballot initiative, or clearly identified legislative 
or regulatory proposal. 
‘‘(D) For any advocacy in support of any 
particular company, industry association, or ad-
vocacy group or the explicit policy positions held 
by such groups. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(E) To direct any individuals to a specific 
type of substance use disorder treatment, treat-
ment facility, medical provider, or form of medi-
cation assisted treatment. 
‘‘(F) To fund any advertising that features 
any elected officials, persons seeking elected of-
fice, cabinet level officials, or other Federal offi-
cials employed pursuant to section 213 of Sched-
ule C of title 5, Code of Federal Regulations. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out this 
section, $25,000,000 for each of fiscal years 2019 through 
2023. 
‘‘§ 1010. National and international coordination 
‘‘(a) DISSEMINATION OF RESEARCH AND INFORMATION 
TO STATES.—The Director shall ensure that drug control 
research and information is effectively disseminated by Na-
tional Drug Control Program Agencies to State and local 
governments and nongovernmental entities involved in de-
mand reduction by— 
‘‘(1) encouraging formal consultation between 
any such agency that conducts or sponsors research, 
and any such agency that disseminates information 
in developing research and information product devel-
opment agendas; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00078
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(2) encouraging such agencies (as appropriate) 
to develop and implement dissemination plans that 
specifically target State and local governments and 
nongovernmental entities involved in demand reduc-
tion; and 
‘‘(3) supporting the substance abuse information 
clearinghouse administered by the Administrator of 
the Substance Abuse and Mental Health Services Ad-
ministration and established in section 501(d)(16) of 
the Public Health Service Act by— 
‘‘(A) encouraging all National Drug Control 
Program Agencies to provide all appropriate and 
relevant information; and 
‘‘(B) supporting the dissemination of infor-
mation to all interested entities. 
‘‘(b) STANDARDS.— 
‘‘(1) DEVELOPMENT.—The Director shall coordi-
nate the development of evidence-based standards de-
veloped by National Drug Control Program Agencies 
and other relevant agencies and non-Federal entities 
to State, local, and Tribal governments and non-
governmental entities related to drug control policies, 
practices, and procedures, such as the investigation of 
drug-related deaths, by— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00079
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) encouraging appropriate agencies and 
State, local, and Tribal governments to develop 
data standards for drug control practices and 
procedures and related statistical data; 
‘‘(B) encouraging information sharing be-
tween appropriate agencies and State, local, and 
Tribal governments of relevant drug control in-
formation and data; 
‘‘(C) establishing a working group of agen-
cies, State, local, and Tribal governments, and 
other relevant stakeholders to discuss and develop 
such standards; and 
‘‘(D) facilitating collaboration among agen-
cies, non-Federal entities, States, local, and Trib-
al governments, and nongovernmental agencies. 
‘‘(2) IMPLEMENTATION.—The Director shall pro-
mote the implementation of the standards described in 
paragraph (1) by— 
‘‘(A) encouraging adoption by providing the 
standards to State and local governments 
through the internet, annual publications or 
periodicals, 
and 
other 
widely-disseminated 
means; and 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00080
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(B) facilitating the use and dissemination 
of such standards among State and local govern-
ments by— 
‘‘(i) providing technical assistance to 
State, local, and Tribal governments seeking 
to adopt or implement such standards; and 
‘‘(ii) coordinating seminars and train-
ing sessions for State, local, and Tribal gov-
ernments seeking to adopt or implement 
such standards. 
‘‘(c) PRIVATE SECTOR.— 
‘‘(1) IN GENERAL.—The Director or the head of 
a National Drug Control Program (as designated by 
the Director) shall coordinate with the private sector 
to promote private research and development of medi-
cations to treat or prevent addiction, including re-
search and development for non-addictive pain man-
agement medication, abuse deterrent formulations, 
medication-assisted treatment, and other addiction re-
search determined to be necessary by the Director 
by— 
‘‘(A) encouraging the sharing of informa-
tion regarding evidence-based treatment addic-
tion findings and related data between agencies 
and the private sector, as appropriate; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00081
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(B) encouraging collaboration between ap-
propriate agencies and the private sector; and 
‘‘(C) providing private sector entities with 
relevant statistical data and information to en-
hance research as permissible. 
‘‘(2) WORKING GROUP.—The Director may estab-
lish a working group of National Drug Control Pro-
gram Agencies, State, local, and Tribal governments, 
and the private sector stakeholders to discuss and dis-
seminate best practices, research and development, 
and other related issues, as appropriate. 
‘‘(d) MODEL ACTS PROGRAM.— 
‘‘(1) IN GENERAL.—The Director shall provide 
for or shall enter into an agreement with a nonprofit 
organization to— 
‘‘(A) advise States on establishing laws and 
policies to address illicit drug use issues; and 
‘‘(B) revise such model State drug laws and 
draft supplementary model State laws to take 
into consideration changes in illicit drug use 
issues in the State involved. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $1,250,000 for each of fiscal years 
2019 through 2023. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00082
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(e) DRUG COURT TRAINING AND TECHNICAL ASSIST-
ANCE PROGRAM.— 
‘‘(1) GRANTS AUTHORIZED.—The Director may 
make a grant to a nonprofit organization for the pur-
pose of providing training and technical assistance to 
drug courts. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $2,000,000 for each of fiscal years 
2019 through 2023. 
‘‘(f) INTERNATIONAL COORDINATION.—The Director 
shall facilitate international drug control coordination ef-
forts. 
‘‘(g) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI-
NATOR.—The Director shall designate or appoint a United 
States State, Local, and Tribal Affairs Coordinator to per-
form the duties of the Office outlined in this section and 
section 1005 and such other duties as may be determined 
by the Director with respect to coordination of drug control 
efforts between agencies and State, local, and Tribal govern-
ments. The Director shall determine whether the coordinator 
position is a career or noncareer position in the Senior Ex-
ecutive Service. 
‘‘§ 1011. Interdiction 
‘‘(a) UNITED STATES INTERDICTION COORDINATOR.— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00083
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(1) IN GENERAL.—The Director shall designate 
or appoint a United States Interdiction Coordinator 
to perform the duties of that position described in 
paragraph (2) and such other duties as may be deter-
mined by the Director with respect to coordination of 
efforts to interdict illicit drugs from entering the 
United States. 
‘‘(2) RESPONSIBILITIES.—The United States 
Interdiction Coordinator shall be responsible to the 
Director for— 
‘‘(A) coordinating the interdiction activities 
of the National Drug Control Program Agencies 
to ensure consistency with the National Drug 
Control Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before March 1 of each year 
and in accordance with paragraph (4), a Na-
tional Interdiction Command and Control Plan 
to ensure the coordination and consistency de-
scribed in subparagraph (A); 
‘‘(C) assessing the sufficiency of assets com-
mitted to illicit drug interdiction by the relevant 
National Drug Control Program Agencies; and 
‘‘(D) advising the Director on the efforts of 
each National Drug Control Program Agency to 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00084
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
implement the National Interdiction Command 
and Control Plan. 
‘‘(3) STAFF.—The Director shall assign such per-
manent staff of the Office as he considers appropriate 
to assist the United States Interdiction Coordinator 
to carry out the responsibilities described in para-
graph (2), and may request that appropriate Na-
tional Drug Control Program Agencies detail or as-
sign staff to assist in carrying out such activities. 
‘‘(4) NATIONAL
INTERDICTION
COMMAND
AND 
CONTROL PLAN.— 
‘‘(A) PURPOSES.—The National Interdic-
tion Command and Control Plan— 
‘‘(i) shall set forth the Government’s 
strategy for drug interdiction; 
‘‘(ii) shall state the specific roles and 
responsibilities of the relevant National 
Drug Control Program Agencies for imple-
menting that strategy; 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy; and 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00085
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(iv) may include recommendations 
about changes to existing agency authorities 
or laws governing interagency relationships. 
‘‘(B) CONSULTATION
WITH
OTHER
AGEN-
CIES.—Before the submission of the National 
Drug Control Strategy or annual supplement re-
quired under section 1005(d), as applicable, the 
United States Interdiction Coordinator shall 
issue the National Interdiction Command and 
Control Plan, in consultation with the other 
members of the Interdiction Committee described 
in subsection (c). 
‘‘(C) REPORT TO CONGRESS.—On or before 
March 1 of each year, the Director, through the 
United States Interdiction Coordinator, shall 
provide to the appropriate congressional commit-
tees, to the Committee on Armed Services and the 
Committee on Homeland Security of the House 
of Representatives, and to the Committee on 
Homeland Security and Governmental Affairs 
and the Committee on Armed Services of the 
Senate, a report that includes— 
‘‘(i) a copy of that year’s National 
Interdiction Command and Control Plan; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00086
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(B) review the annual National Interdic-
tion Command and Control Plan, and provide 
advice to the Director and the United States 
Interdiction Coordinator concerning that plan; 
and 
‘‘(C) provide such other advice to the Direc-
tor concerning drug interdiction strategy and 
policies as the committee determines is appro-
priate. 
‘‘(2) CHAIR.—The Director shall designate one of 
the members of the Interdiction Committee to serve as 
chair. 
‘‘(3) MEETINGS.—The members of the Interdic-
tion Committee shall meet, in person and not through 
any delegate or representative, at least once per cal-
endar year, before March 1. At the call of the Director 
or the chair, the Interdiction Committee may hold ad-
ditional meetings, which shall be attended by the 
members in person, or through such delegates or rep-
resentatives as the members may choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the chair of the Interdiction Committee 
shall submit to the Director and to the appropriate 
congressional committees a report describing the re-
sults of the meetings and any significant findings of 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00088
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
the committee during the previous 12 months. Such 
report may include a classified annex. 
‘‘§ 1012. Treatment coordinator 
‘‘(a) UNITED STATES TREATMENT COORDINATOR.— 
‘‘(1) IN GENERAL.—The Director shall designate 
or appoint a United States Treatment Coordinator to 
perform the responsibilities of that position described 
in paragraph (2) and such other duties as may be de-
termined by the Director with respect to coordination 
of efforts to expand the availability of substance use 
disorder treatment with the goal of eliminating the 
unmet treatment need. 
‘‘(2) RESPONSIBILITIES.—The United States 
Treatment Coordinator shall be responsible to the Di-
rector for— 
‘‘(A) coordinating the activities of the Na-
tional Drug Control Program Agencies under-
taken to expand the availability of evidence- 
based substance use disorder treatment to ensure 
consistency with the National Drug Control 
Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before March 1 of each year 
and in accordance with paragraph (4), a Na-
tional Treatment Plan to ensure the coordina-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00089
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
tion and consistency described in subparagraph 
(A); 
‘‘(C) assessing the sufficiency of Federal re-
sources directed to substance use disorder treat-
ment by the relevant National Drug Control Pro-
gram Agencies; 
‘‘(D) encouraging the adoption by all sub-
stance use disorder treatment providers of evi-
dence-based standards to guide all aspects of 
treatment provided; and 
‘‘(E) advising the Director on the efforts of 
each National Drug Control Program Agency to 
implement the National Treatment Plan. 
‘‘(3) STAFF.—The Director shall assign such per-
manent staff of the Office of the United States Treat-
ment Coordinator as the Director determines to be ap-
propriate to assist the United States Treatment Coor-
dinator to carry out the responsibilities described in 
paragraph (2), and may request that appropriate Na-
tional Drug Control Program Agencies detail or as-
sign staff to assist in carrying out such responsibil-
ities. 
‘‘(4) NATIONAL TREATMENT PLAN.— 
‘‘(A) PURPOSES.—The National Treatment 
Plan— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00090
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(i) shall identify the unmet need for 
treatment for evidence-based substance use 
disorders including opioid use disorders, 
and set forth the Government’s strategy for 
closing the gap between available and need-
ed treatment through all sources; 
‘‘(ii) shall describe the specific roles 
and responsibilities of the relevant National 
Drug Control Program Agencies for imple-
menting that strategy; 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy; 
‘‘(iv) shall identify the resources, in-
cluding private sources, required to elimi-
nate the unmet need for evidence-based sub-
stance use disorder treatment; and 
‘‘(v) may include recommendations 
about changes to existing agency authorities 
or laws governing interagency relationships. 
‘‘(B) CONSULTATION
WITH
OTHER
AGEN-
CIES.—Before the submission of the National 
Treatment Strategy or annual supplement re-
quired under section 1005(d), as applicable, the 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00091
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
United States Treatment Coordinator shall issue 
the National Treatment Plan, in consultation 
with the other members of the Interdiction Com-
mittee described in subsection (b). 
‘‘(C) REPORT TO CONGRESS.—On or before 
March 1 of each year, the Director, through the 
United States Treatment Coordinator, shall pro-
vide to the appropriate congressional committees 
a report that includes a copy of that year’s Na-
tional Treatment Plan; 
‘‘(b) TREATMENT COMMITTEE.— 
‘‘(1) IN
GENERAL.—The Treatment Committee 
shall meet to— 
‘‘(A) review and discuss the adequacy of 
evidence-based substance use disorder treatment 
as well as the unmet need for treatment; 
‘‘(B) review and discuss the status of the 
implementation of the National Treatment Plan; 
and 
‘‘(C) provide such other advice to the Direc-
tor concerning substance use disorder treatment 
initiatives as the committee determines is appro-
priate. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00092
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(2) CHAIR.—The Director shall designate one of 
the members of the Treatment Committee to serve as 
chair. 
‘‘(3) MEETINGS.—The members of the Treatment 
Committee shall meet, in person and not through any 
delegate or representative, at least once per calendar 
year, before March 1. At the call of the Director or 
the chair, the Treatment Committee may hold addi-
tional meetings, which shall be attended by the mem-
bers in person, or through such delegates or represent-
atives as the members may choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the chair of the Treatment Committee shall 
submit to the Director and to the appropriate con-
gressional committees a report describing the results 
of the meetings and any significant findings of the 
committee during the previous 12 months. Such re-
port may include a classified annex. 
‘‘§ 1013. Critical information coordination 
‘‘(a) NATIONAL DRUG CONTROL FUSION CENTER.— 
‘‘(1) ESTABLISHMENT.—The Director shall, in 
consultation with the head of each National Drug 
Control Program Agency, designate an agency to es-
tablish a National Drug Control Fusion Center (re-
ferred to in this section as the ‘Center’). The Center 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00093
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
shall operate under the authority of the Director and 
shall work with the National Drug Control Program 
Agencies to collect, compile, analyze, and facilitate the 
sharing of data on the use of illicit drugs, treatment 
for substance use disorder, and interdiction of illicit 
drugs. The Center shall be considered a ‘statistical 
agency or unit’, as that term is defined in section 502 
of the Confidential Information Protection and Sta-
tistical Efficiency Act of 2002 (44 U.S.C. 3501 note) 
and shall have the necessary independence to ensure 
any data or information acquired by an agency 
under a pledge of confidentiality and for exclusively 
statistical purposes is used exclusively for statistical 
purposes. 
‘‘(2) CENTER DIRECTOR.—There shall be at the 
head of the Center a Center Director who shall be ap-
pointed by the Director from among individuals 
qualified and distinguished in data governance and 
statistical analysis. 
‘‘(3) DATA COMPILATION.—The Director, acting 
through the Center Director, shall do the following: 
‘‘(A) Coordinate data collection activities 
among the National Drug Control Program 
Agencies. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00094
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(B) Collect information not otherwise col-
lected by National Drug Control Program Agen-
cies as necessary to inform the National Drug 
Control Strategy. 
‘‘(C) Compile and analyze any data re-
quired to be collected under this chapter. 
‘‘(D) Disseminate technology, as appro-
priate, to States and local jurisdictions to enable 
or improve the collection of data on drug use, in-
cluding the recordation of the occurrence of fatal 
and non-fatal drug overdoses. 
‘‘(E) Compile information collected by Na-
tional Drug Control Program Agencies on grants 
issued through any National Drug Control Pro-
gram, including for any grant the following: 
‘‘(i) The recipient. 
‘‘(ii) The amount. 
‘‘(iii) The intended purpose. 
‘‘(iv) Any evidence of the efficacy of the 
outcomes achieved by the program funded 
through the grant. 
‘‘(v) Any assessments of how the grant 
met its intended purpose. 
‘‘(4) TOXICOLOGY SCREENING.— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00095
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) ESTABLISHMENT.—The Center Direc-
tor may establish a toxicology screening program 
that engages in— 
‘‘(i) secondary analysis of urine sam-
ples that would otherwise be discarded by— 
‘‘(I) hospitals and drug treatment 
programs; 
‘‘(II) correctional facilities, book-
ing sites, probation programs, drug 
courts, and related facilities; and 
‘‘(III) coroners and medical exam-
iners; and 
‘‘(ii) analysis of other physical sam-
ples, as determined by the Center Director 
to be valuable for understanding the preva-
lence of any illicit drug. 
‘‘(B) 
DE-IDENTIFICATION
OF
INFORMA-
TION.—The Center Director shall ensure that no 
samples have any personally identifiable infor-
mation prior to collection. 
‘‘(C) LIMITATION
ON
USE.—No data ob-
tained from analysis conducted under this para-
graph may be used as evidence in any pro-
ceeding. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00096
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(D) STATE PROGRAM.—The Center Direc-
tor may establish a program that enables States 
and local jurisdictions to submit up to 20 urine 
samples per year for toxicology analysis for the 
purposes of identifying substances present in in-
dividuals who have suffered fatal drug overdoses. 
‘‘(5) AUTHORITY TO CONTRACT.—The Director 
may award contracts, enter into interagency agree-
ments, manage individual projects, and conduct other 
operational activities under this subsection. 
‘‘(b) CRITICAL DRUG CONTROL INFORMATION
AND 
EVIDENCE PLAN.— 
‘‘(1) IN GENERAL.—Not later than the first Mon-
day in February of each year, the Director shall sub-
mit to Congress a systematic plan for increasing data 
collection to enable real-time surveillance of drug con-
trol threats, developing analysis and monitoring ca-
pabilities, and identifying and addressing policy 
questions relevant to the National Drug Control Pol-
icy, Strategy, and Program. Such plan shall be made 
available on the public online portal of the Office, 
shall cover at least a 4-year period beginning with the 
first fiscal year following the fiscal year in which the 
plan is submitted and published, and contain the fol-
lowing: 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00097
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(A) A list of policy-relevant questions for 
which the Director and each National Drug Con-
trol Program Agency intends to develop evidence 
to support the National Drug Control Program 
and Strategy. 
‘‘(B) A list of data the Director and each 
National Drug Control Program Agency intends 
to collect, use, or acquire to facilitate the use of 
evidence in drug control policymaking and mon-
itoring. 
‘‘(C) A list of methods and analytical ap-
proaches that may be used to develop evidence to 
support the National Drug Control Program and 
Strategy and related policy. 
‘‘(D) A list of any challenges to developing 
evidence to support policymaking, including any 
barriers to accessing, collecting, or using relevant 
data. 
‘‘(E) A description of the steps the Director 
and the head of each National Drug Control Pro-
gram Agency will take to effectuate the plan. 
‘‘(F) Any other relevant information as de-
termined by the Director. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00098
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
‘‘(2) CONSULTATION.—In developing the plan re-
quired under paragraph (1), the Director shall con-
sult with the following: 
‘‘(A) The public. 
‘‘(B) Any evaluation or analysis units and 
personnel of the Office. 
‘‘(C) Office officials responsible for imple-
menting privacy policy. 
‘‘(D) Office officials responsible for data 
governance. 
‘‘(E) The appropriate congressional com-
mittees. 
‘‘(F) Any other individual or entity as de-
termined by the Director. 
‘‘(c) EVIDENCE-BASED POLICY.— 
‘‘(1) HARM REDUCTION PROGRAMS.—When de-
veloping the national drug control policy, any policy 
of the Director, including policies relating to syringe 
exchange programs for intravenous drug users, shall 
be based on the best available medical and scientific 
evidence regarding the effectiveness of such policy in 
promoting individual health, preventing the spread of 
infectious disease and the impact of such policy on 
drug addiction and use. In making any policy relat-
ing to harm reduction programs, the Director shall 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00099
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
100 
consult with the National Institutes of Health and the 
National Academy of Sciences. 
‘‘(2) FUND RESTRICTION FOR THE LEGALIZATION 
OF
CONTROLLED
SUBSTANCES.—The Director shall 
ensure that no Federal funds appropriated to the Of-
fice shall be expended for any study or contract relat-
ing to the legalization (for a medical use or any other 
use) for which a listing in schedule I is in effect 
under section 202 of the Controlled Substances Act 
(21 U.S.C. 812). 
‘‘(d) DRUG CONTROL DATA DASHBOARD.— 
‘‘(1) ESTABLISHMENT.—The Director, in con-
sultation with the Center Director, shall establish and 
maintain a data dashboard on the online portal of 
the Office to be known as the ‘Drug Control Data 
Dashboard’. The Director shall ensure the user inter-
face of the dashboard is constructed with modern de-
sign standards. To the extent practicable, the data 
made available on the dashboard shall be publicly 
available in a machine-readable format and search-
able by year, agency, drug, and location. 
‘‘(2) DATA.—The data included in the Drug 
Control Data Dashboard shall be updated not less fre-
quently than quarterly and shall include, at a min-
imum, the following: 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00100
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
101 
‘‘(A) For each substance identified under 
section 1005(c)(1)(A)(i)— 
‘‘(i) the total amount seized and dis-
rupted in the calendar year and each of the 
previous 3 calendar years; 
‘‘(ii) the known and estimated flows 
into the United States from all sources in 
the calendar year and each of the previous 
3 calendar years; 
‘‘(iii) the total amount of known flows 
that could not be interdicted or disrupted in 
the calendar year and each of the previous 
3 calendar years; 
‘‘(iv) the known and estimated levels of 
domestic production in the calendar year 
and each of the previous three calendar 
years, including the levels of domestic pro-
duction if the drug is a prescription drug, 
as determined under the Federal Food, 
Drug, and Cosmetic Act, for which a listing 
is in effect under section 202 of the Con-
trolled Substances Act (21 U.S.C. 812); and 
‘‘(v) the average street price for the cal-
endar year and the highest known street 
price during the preceding 10-year period. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00101
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
102 
‘‘(B) For the calendar year and each of the 
previous three years data sufficient to show, 
disaggregated by State and, to the extent feasible, 
by region within a State, county, or city, the fol-
lowing: 
‘‘(i) The number of fatal and non-fatal 
overdoses caused by each drug identified 
under subparagraph (A)(i). 
‘‘(ii) The prevalence of substance use 
disorders. 
‘‘(iii) The number of individuals who 
have received substance use disorder treat-
ment, including medication assisted treat-
ment, for a substance use disorder, includ-
ing treatment provided through publicly-fi-
nanced health care programs. 
‘‘(iv) The extent of the unmet need for 
substance use disorder treatment, including 
the unmet need for medication-assisted 
treatment. 
‘‘(C) Data sufficient to show the extent of 
prescription drug diversion, trafficking, and 
misuse in the calendar year and each of the pre-
vious 3 calendar years. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00102
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
103 
‘‘(D) Any quantifiable measures the Direc-
tor determines to be appropriate to detail 
progress toward the achievement of the goals of 
the National Drug Control Strategy. 
‘‘(e) ACCESS TO INFORMATION.— 
‘‘(1) IN GENERAL.—Upon the request of the Di-
rector, the head of any National Drug Control Pro-
gram Agency shall cooperate with and provide to the 
Director any statistics, studies, reports, and other in-
formation prepared or collected by the agency con-
cerning the responsibilities of the agency under the 
National Drug Control Strategy that relate to— 
‘‘(A) drug control; or 
‘‘(B) the manner in which amounts made 
available to that agency for drug control are 
being used by that agency. 
‘‘(2) PROTECTION OF INTELLIGENCE INFORMA-
TION.— 
‘‘(A) IN
GENERAL.—The authorities con-
ferred on the Office and the Director by this 
chapter shall be exercised in a manner consistent 
with provisions of the National Security Act of 
1947 (50 U.S.C. 401 et seq.). The Director of Na-
tional Intelligence shall prescribe such regula-
tions as may be necessary to protect information 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00103
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
104 
provided pursuant to this chapter regarding in-
telligence sources and methods. 
‘‘(B) DUTIES OF DIRECTOR.—The Director 
of National Intelligence and the Director of the 
Central Intelligence Agency shall, to the max-
imum extent practicable in accordance with sub-
paragraph (A), render full assistance and sup-
port to the Office and the Director. 
‘‘(3) REQUIRED REPORTS FROM NATIONAL DRUG 
CONTROL
AGENCIES.—The head of each National 
Drug Control Program Agency shall submit to the Di-
rector such information and reports as requested from 
such National Drug Control Program Agency by the 
Director, which shall include from the appropriate 
National Drug Control Program Agencies: 
‘‘(A) Not later than July 1 of each year, the 
head of a designated National Drug Control Pro-
gram Agency shall submit to the Director and 
the appropriate congressional committees an as-
sessment of the quantity of illegal drug cultiva-
tion and manufacturing in the United States on 
lands owned or under the jurisdiction of their re-
spective agencies that was seized or eradicated by 
their personnel during the preceding calendar 
year. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00104
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
105 
‘‘(B) Not later than July 1 of each year, the 
head of a designated National Drug Control Pro-
gram Agency shall submit to the Director and 
the appropriate congressional committees infor-
mation for the preceding year regarding— 
‘‘(i) the number and type of seizures of 
drugs by each component of the agency seiz-
ing drugs, as well as statistical information 
on the geographic areas of such seizures; 
and 
‘‘(ii) the number of air and maritime 
patrol hours primarily dedicated to drug 
supply reduction missions undertaken by 
each component of the agency. 
‘‘(C) Not later than July 1 of each year, the 
head of a designated National Drug Control Pro-
gram Agency shall submit to the Director and 
the appropriate congressional committees infor-
mation for the preceding year regarding the 
number of air and maritime patrol hours pri-
marily dedicated to drug supply reduction mis-
sions undertaken by each component of the agen-
cy. 
‘‘(D) Not later than July 1 of each year, the 
head of a designated National Drug Control Pro-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00105
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
106 
gram Agency shall submit to the Director and 
the appropriate congressional committees infor-
mation for the preceding year regarding the 
number and type of— 
‘‘(i) arrests for drug violations; 
‘‘(ii) prosecutions for drug violations 
by United States Attorneys; and 
‘‘(iii) seizures of drugs by each compo-
nent of the Department of Justice seizing 
drugs, as well as statistical information on 
the geographic areas of such seizures. 
‘‘(f) DATA EXCHANGE STANDARDS
FOR IMPROVED 
INTEROPERABILITY.— 
‘‘(1) INTERAGENCY
AND
INTERGOVERNMENTAL 
DESIGNATION AND USE OF DATA EXCHANGE STAND-
ARDS WORKING GROUP.—The Director shall establish 
a working group of National Drug Control Program 
Agencies, State, local and Tribal government health 
and law enforcement agencies, and data governance 
experts to develop consensus data exchange standards 
for necessary categories of information that allow ef-
fective electronic exchange of information between 
States, between State agencies, between States and 
National Drug Control Program Agencies, and any 
other drug control relevant data exchange. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00106
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
107 
‘‘(2) DATA EXCHANGE STANDARDS MUST BE NON-
PROPRIETARY
AND
INTEROPERABLE.—The data ex-
change standards designated under paragraph (1) 
shall, to the extent practicable, be nonproprietary and 
interoperable. 
‘‘(3) OTHER
REQUIREMENTS.—In designating 
data exchange standards under this subsection, the 
working group shall, to the extent practicable, incor-
porate— 
‘‘(A) interoperable standards developed and 
maintained by an international voluntary con-
sensus standards body, as defined by the Office 
of Management and Budget; 
‘‘(B) interoperable standards developed and 
maintained by intergovernmental partnerships; 
and 
‘‘(C) interoperable standards developed and 
maintained by Federal entities with authority 
over contracting and financial assistance. 
‘‘(4) DATA EXCHANGE STANDARDS FOR FEDERAL 
REPORTING.— 
‘‘(A) DESIGNATION.—The Director may, in 
consultation with the working group established 
under this section, National Drug Control Pro-
gram Agencies, and State, local, and Tribal gov-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00107
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
108 
ernments, designate data exchange standards to 
govern Federal reporting and exchange require-
ments for National Drug Control Programs, as 
appropriate. 
‘‘(B) REQUIREMENTS.—The data exchange 
reporting standards required by subparagraph 
(A) shall, to the extent practicable— 
‘‘(i) incorporate a widely accepted, 
nonproprietary, searchable, machine-read-
able format; 
‘‘(ii) be consistent with and implement 
applicable accounting principles; 
‘‘(iii) be implemented in a manner 
that is cost-effective and improves program 
efficiency and effectiveness; and 
‘‘(iv) be capable of being continually 
upgraded as necessary. 
‘‘(C) INCORPORATION OF NONPROPRIETARY 
STANDARDS.—In 
designating 
data 
exchange 
standards under this paragraph, the Director 
shall, to the extent practicable, incorporate exist-
ing nonproprietary standards. 
‘‘(D) RULE OF CONSTRUCTION.—Nothing in 
this paragraph shall be construed to require a 
change to existing data exchange standards for 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00108
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
109 
Federal reporting about a program referred to in 
this section, if the head of the agency responsible 
for administering the program finds the stand-
ards to be effective and efficient. 
‘‘(5) TERMINATION.—The working group estab-
lished under paragraph (1) shall terminate not ear-
lier than 60 days after the public notification of ter-
mination by the Director. 
‘‘(g) ANNUAL DATA COLLECTION AND DISSEMINATION 
REQUIREMENTS.— 
‘‘(1) IN
GENERAL.—The Director shall collect 
and disseminate, as appropriate, such information as 
the Director determines is appropriate, but not less 
than the information described in this subsection. To 
the extent practicable, the data shall be publicly 
available in a machine-readable format on the Drug 
Control Data Dashboard, be searchable by year, agen-
cy, drug, and location, and cover not less than the 
previous 10-year period. 
‘‘(2) PREPARATION AND DISSEMINATION OF IN-
FORMATION.—The Director shall prepare and dis-
seminate the following: 
‘‘(A) An assessment of current illicit drug 
use (including inhalants and steroids) and avail-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00109
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
110 
ability, impact of illicit drug use, and treatment 
availability, which assessment shall include— 
‘‘(i) estimates of drug prevalence and 
frequency of use as measured by national, 
State, and local surveys of illicit drug use 
and by other special studies of non-
dependent and dependent illicit drug use; 
‘‘(ii) illicit drug use in the workplace 
and the productivity lost by such use; and 
‘‘(iii) illicit drug use by arrestees, pro-
bationers, and parolees. 
‘‘(B) An assessment of the reduction of il-
licit drug availability, for each drug identified 
under section 1005(c)(1)(A)(i), as measured by— 
‘‘(i) the quantities of such drug avail-
able for consumption in the United States; 
‘‘(ii) the amount of such drug entering 
the United States; 
‘‘(iii) the number of illicit drug manu-
facturing laboratories seized and destroyed 
of each relevant drug and the number of 
hectares cultivated and destroyed domesti-
cally and in other countries of each relevant 
drug; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00110
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
111 
‘‘(iv) the number of metric tons of such 
drug seized; and 
‘‘(v) changes in the price and purity of 
such drug. 
‘‘(C) An assessment of the reduction of the 
consequences of illicit drug use and availability, 
which shall include— 
‘‘(i) the cost of treating substance use 
disorder in the United States, such as the 
quantity of illicit drug-related services pro-
vided; 
‘‘(ii) the annual national health care 
cost of illicit drug use; and 
‘‘(iii) the extent of illicit drug-related 
crime and criminal activity. 
‘‘(D) A determination of the status of drug 
treatment in the United States, by assessing— 
‘‘(i) public and private treatment utili-
zation; and 
‘‘(ii) the number of illicit drug users 
the Director estimates meet diagnostic cri-
teria for treatment. 
‘‘(E) A summary of the efforts made to co-
ordinate with private sector entities to conduct 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00111
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
112 
private research and development of medications 
to treat addiction by— 
‘‘(i) screening chemicals for potential 
therapeutic value; 
‘‘(ii) developing promising compounds; 
‘‘(iii) conducting clinical trials; 
‘‘(iv) seeking Food and Drug Adminis-
tration approval for drugs to treat addic-
tion; 
‘‘(v) marketing the drug for the treat-
ment of addiction; 
‘‘(vi) urging physicians to use the drug 
in the treatment of addiction; and 
‘‘(vii) encouraging insurance compa-
nies to reimburse the cost of the drug for the 
treatment of addiction. 
‘‘§ 1014. Annual audit and investigation requirements 
‘‘(a) PERIODIC GOVERNMENT ACCOUNTABILITY OF-
FICE AUDITS OF PROGRAMS AND OPERATIONS.—Not later 
than December 31, 2019, and every 3 years thereafter, the 
Comptroller General shall— 
‘‘(1) conduct and supervise an audit and inves-
tigation relating to the programs and operations of— 
‘‘(A) the Office; or 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00112
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
113 
‘‘(B) certain programs within the Office, in-
cluding— 
‘‘(i) the High Intensity Drug Traf-
ficking Areas Program; and 
‘‘(iii) the media campaign under sec-
tion 1009(d); and 
‘‘(2) submit to the Director and the appropriate 
congressional committees a report containing an eval-
uation of and recommendations on the— 
‘‘(A) policies and activities of the programs 
and operations subject to the audit and inves-
tigation; 
‘‘(B) economy, efficiency, and effectiveness 
in the administration of the reviewed programs 
and operations; and 
‘‘(C) policy or management changes needed 
to prevent and detect fraud and abuse in such 
programs and operations. 
‘‘§ 1015. Authorization of appropriations 
‘‘There are authorized to be appropriated to carry out 
this chapter, except as otherwise specified, to remain avail-
able until expended, $18,400,000 for each of fiscal years 
2019 through 2023. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00113
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
114 
‘‘SUBCHAPTER II—HIGH INTENSITY DRUG 
TRAFFICKING AREAS PROGRAM 
‘‘§ 1021. High intensity drug trafficking areas pro-
gram 
‘‘(a) ESTABLISHMENT.— 
‘‘(1) IN GENERAL.—There is established in the 
Office a program to be known as the High Intensity 
Drug Trafficking Areas Program (in this section re-
ferred to as the ‘Program’). 
‘‘(2) PURPOSE.—The purpose of the Program is 
to reduce drug trafficking and drug production in the 
United States by— 
‘‘(A) facilitating cooperation among Fed-
eral, State, local, and Tribal law enforcement 
agencies to share information and implement co-
ordinated enforcement activities; 
‘‘(B) enhancing law enforcement intelligence 
sharing among Federal, State, local, and Tribal 
law enforcement agencies; 
‘‘(C) providing reliable law enforcement in-
telligence to law enforcement agencies needed to 
design effective enforcement strategies and oper-
ations; and 
‘‘(D) supporting coordinated law enforce-
ment strategies which maximize use of available 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00114
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
115 
resources to reduce the supply of illegal drugs in 
designated areas and in the United States as a 
whole. 
‘‘(b) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consultation 
with the Attorney General, the Secretary of the Treas-
ury, the Secretary of Homeland Security, heads of the 
National Drug Control Program Agencies, and the 
Governor of each applicable State, may designate any 
specified area of the United States as a high intensity 
drug trafficking area. 
‘‘(2) ACTIVITIES.—After making a designation 
under paragraph (1) and in order to provide Federal 
assistance to the area so designated, the Director 
may— 
‘‘(A) obligate such sums as are appropriated 
for the Program; 
‘‘(B) direct the temporary reassignment of 
Federal personnel to such area, subject to the ap-
proval of the head of the agency that employs 
such personnel; 
‘‘(C) take any other action authorized under 
this chapter to provide increased Federal assist-
ance to those areas; and 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00115
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
116 
‘‘(D) coordinate activities under this section 
(specifically administrative, recordkeeping, and 
funds management activities) with State, local, 
and Tribal officials. 
‘‘(c) PETITIONS
FOR DESIGNATION.—The Director 
shall establish and maintain regulations under which a coa-
lition of interested law enforcement agencies from an area 
may petition for designation as a high intensity drug traf-
ficking area (in this section referred to as the ‘HIDTA’). 
Such regulations shall provide for a regular review by the 
Director of the petition, including a recommendation re-
garding the merit of the petition to the Director by a panel 
of qualified, independent experts. 
‘‘(d) FACTORS FOR CONSIDERATION.—In considering 
whether to designate an area under this section as a high 
intensity drug trafficking area, the Director shall consider, 
in addition to such other criteria as the Director considers 
to be appropriate, the extent to which— 
‘‘(1) the area is a significant center of illegal 
drug production, manufacturing, importation, or dis-
tribution; 
‘‘(2) State, local, and Tribal law enforcement 
agencies have committed resources to respond to the 
drug trafficking problem in the area, thereby indi-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00116
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
117 
cating a determination to respond aggressively to the 
problem; 
‘‘(3) drug-related activities in the area are hav-
ing a significant harmful impact in the area, and in 
other areas of the country; and 
‘‘(4) a significant increase in allocation of Fed-
eral resources is necessary to respond adequately to 
drug-related activities in the area. 
‘‘(e) ORGANIZATION OF HIGH INTENSITY DRUG TRAF-
FICKING AREAS.— 
‘‘(1) EXECUTIVE BOARD AND OFFICERS.—To be 
eligible for funds appropriated under this section, 
each high intensity drug trafficking area shall be gov-
erned by an Executive Board. The Executive Board 
shall designate a chairman, vice chairman, and any 
other officers to the Executive Board that it deter-
mines are necessary. 
‘‘(2) RESPONSIBILITIES.—The Executive Board 
of a high intensity drug trafficking area shall be re-
sponsible for— 
‘‘(A) providing direction and oversight in 
establishing and achieving the goals of the high 
intensity drug trafficking area; 
‘‘(B) managing the funds of the high inten-
sity drug trafficking area; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00117
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
118 
‘‘(C) reviewing and approving all funding 
proposals consistent with the overall objective of 
the high intensity drug trafficking area; and 
‘‘(D) reviewing and approving all reports to 
the Director on the activities of the high inten-
sity drug trafficking area. 
‘‘(3) BOARD
REPRESENTATION.—None of the 
funds appropriated under this section may be ex-
pended for any high intensity drug trafficking area, 
or for a partnership or region of a high intensity 
drug trafficking area, if the Executive Board for such 
area, region, or partnership, does not apportion an 
equal number of votes between representatives of par-
ticipating agencies and representatives of partici-
pating State, local, and Tribal agencies. Where it is 
impractical for an equal number of representatives of 
agencies and State, local, and Tribal agencies to at-
tend a meeting of an Executive Board in person, the 
Executive Board may use a system of proxy votes or 
weighted votes to achieve the voting balance required 
by this paragraph. 
‘‘(4) NO AGENCY RELATIONSHIP.—The eligibility 
requirements of this section are intended to ensure the 
responsible use of Federal funds. Nothing in this sec-
tion is intended to create an agency relationship be-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00118
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
119 
tween individual high intensity drug trafficking areas 
and the Federal Government. 
‘‘(f) USE OF FUNDS.—The Director shall ensure that 
not more than 5 percent of Federal funds appropriated for 
the Program are expended for drug treatment programs and 
not more than 5 percent of the Federal funds appropriated 
for the Program are expended for drug prevention pro-
grams. 
‘‘(g) COUNTERTERRORISM ACTIVITIES.— 
‘‘(1) ASSISTANCE
AUTHORIZED.—The Director 
may authorize use of resources available for the Pro-
gram to assist Federal, State, local, and Tribal law 
enforcement agencies in investigations and activities 
related to terrorism and prevention of terrorism, espe-
cially but not exclusively with respect to such inves-
tigations and activities that are also related to drug 
trafficking. 
‘‘(2) LIMITATION.—The Director shall ensure— 
‘‘(A) that assistance provided under para-
graph (1) remains incidental to the purpose of 
the Program to reduce drug availability and 
carry out drug-related law enforcement activi-
ties; and 
‘‘(B) that significant resources of the Pro-
gram are not redirected to activities exclusively 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00119
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
120 
related to terrorism, except on a temporary basis 
under extraordinary circumstances, as deter-
mined by the Director. 
‘‘(h) ROLE
OF DRUG ENFORCEMENT ADMINISTRA-
TION.—The Director, in consultation with the Attorney 
General, shall ensure that a representative of the Drug En-
forcement Administration is included in the Intelligence 
Support Center for each high intensity drug trafficking 
area. 
‘‘(i) EMERGING THREAT RESPONSE FUND.— 
‘‘(1) IN GENERAL.—Subject to the availability of 
appropriations, the Director may expend up to 10 
percent of the amounts appropriated under this sec-
tion on a discretionary basis, in accordance with the 
criteria established under paragraph (2)— 
‘‘(A) to respond to any emerging drug traf-
ficking threat in an existing high intensity drug 
trafficking area; 
‘‘(B) to establish a new high intensity drug 
trafficking area; or 
‘‘(C) to expand an existing high intensity 
drug trafficking area. 
‘‘(2) CONSIDERATION OF IMPACT.—In allocating 
funds under this subsection, the Director shall con-
sider— 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00120
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
121 
‘‘(A) the impact of activities funded on re-
ducing overall drug traffic in the United States, 
or minimizing the probability that an emerging 
drug trafficking threat will spread to other areas 
of the United States; and 
‘‘(B) such other criteria as the Director con-
siders appropriate. 
‘‘(j) ANNUAL HIDTA PROGRAM BUDGET SUBMIS-
SIONS.—As part of the documentation that supports the 
President’s annual budget request for the Office, the Direc-
tor shall submit to Congress a budget justification that in-
cludes— 
‘‘(1) the amount proposed for each HIDTA, con-
ditional upon a review by the Office of the request 
submitted by such HIDTA and the performance of 
such HIDTA, with supporting narrative descriptions 
and rationale for each request; 
‘‘(2) a detailed justification that explains— 
‘‘(A) the reasons for the proposed funding 
level and how such funding level was determined 
based on a current assessment of the drug traf-
ficking threat in each high intensity drug traf-
ficking area; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00121
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
122 
‘‘(B) how such funding will ensure that the 
goals and objectives of each such area will be 
achieved; and 
‘‘(C) how such funding supports the Na-
tional Drug Control Strategy; and 
‘‘(3) the amount of HIDTA funds used to inves-
tigate and prosecute organizations and individuals 
trafficking in each major illicit drug, as identified by 
the Director, in the prior calendar year, and a de-
scription of how those funds were used. 
‘‘(k) HIDTA ANNUAL EVALUATION REPORT.—As part 
of each National Drug Control Evaluation assessment 
under section 1006, the Director shall include, for each des-
ignated high intensity drug trafficking area, a report 
that— 
‘‘(1) describes— 
‘‘(A) the specific purposes for the high in-
tensity drug trafficking area; and 
‘‘(B) the specific long-term and short-term 
goals and objectives for the high intensity drug 
trafficking area; 
‘‘(2) includes an evaluation of the performance of 
the high intensity drug trafficking area in accom-
plishing the specific long-term and short-term goals 
and objectives identified under subparagraph (1)(B); 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00122
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
123 
‘‘(3) assesses the number and operation of all fed-
erally funded drug enforcement task forces within 
such high intensity drug trafficking area; 
‘‘(4) describes— 
‘‘(A) each Federal, State, local, and Tribal 
drug enforcement task force operating in such 
high intensity drug trafficking area; 
‘‘(B) how such task forces coordinate with 
each other, with any high intensity drug traf-
ficking area task force, and with investigations 
receiving funds from the Organized Crime and 
Drug Enforcement Task Force; 
‘‘(C) what steps, if any, each such task force 
takes to share information regarding drug traf-
ficking and drug production with other federally 
funded drug enforcement task forces in the high 
intensity drug trafficking area; 
‘‘(D) the role of the high intensity drug traf-
ficking area in coordinating the sharing of such 
information among task forces; 
‘‘(E) the nature and extent of cooperation 
by each Federal, State, local, and Tribal partici-
pant in ensuring that such information is shared 
among law enforcement agencies and with the 
high intensity drug trafficking area; 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00123
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
124 
‘‘(F) the nature and extent to which infor-
mation sharing and enforcement activities are 
coordinated with joint terrorism task forces in 
the high intensity drug trafficking area; and 
‘‘(G) any recommendations for measures 
needed to ensure that task force resources are uti-
lized efficiently and effectively to reduce the 
availability of illegal drugs in the high intensity 
drug trafficking areas; and 
‘‘(5) in consultation with the Director of Na-
tional Intelligence— 
‘‘(A) evaluates existing and planned law en-
forcement intelligence systems supported by such 
high intensity drug trafficking area, or utilized 
by task forces receiving any funding under the 
Program, including the extent to which such sys-
tems ensure access and availability of law en-
forcement intelligence to Federal, State, local, 
and Tribal law enforcement agencies within the 
high intensity drug trafficking area and outside 
of such area; 
‘‘(B) evaluates the extent to which Federal, 
State, local, and Tribal law enforcement agencies 
participating in each high intensity drug traf-
ficking area are sharing law enforcement intel-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00124
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
125 
ligence information to assess current drug traf-
ficking threats and design appropriate enforce-
ment strategies; and 
‘‘(C) identifies the measures needed to im-
prove effective sharing of information and law 
enforcement intelligence regarding drug traf-
ficking and drug production among Federal, 
State, local, and Tribal law enforcement partici-
pating in a high intensity drug trafficking area, 
and between such agencies and similar agencies 
outside the high intensity drug trafficking area. 
‘‘(l) COORDINATION OF LAW ENFORCEMENT INTEL-
LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN-
FORCEMENT TASK FORCE PROGRAM.— 
‘‘(1) DRUG ENFORCEMENT INTELLIGENCE SHAR-
ING.—The Director, in consultation with the Attorney 
General, shall ensure that any drug enforcement intel-
ligence obtained by the Intelligence Support Center 
for each high intensity drug trafficking area is 
shared, on a timely basis, with the drug intelligence 
fusion center operated by the Organized Crime Drug 
Enforcement Task Force of the Department of Justice. 
‘‘(2) 
CERTIFICATION.—Before 
the 
Director 
awards any funds to a high intensity drug trafficking 
area, the Director shall certify that the law enforce-
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00125
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
126 
ment entities participating in that HIDTA are pro-
viding laboratory seizure data to the national clan-
destine laboratory database at the El Paso Intel-
ligence Center. 
‘‘(m) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out this 
section $280,000,000 for each fiscal years 2019 through 
2023. 
‘‘(n) SPECIFIC PURPOSES.— 
‘‘(1) IN
GENERAL.—The Director shall ensure 
that, of the amounts appropriated for a fiscal year for 
the Program, at least 2.5 percent is used in high in-
tensity drug trafficking areas with severe neighbor-
hood safety and illegal drug distribution problems. 
‘‘(2) REQUIRED USES.—The funds used under 
paragraph (1) shall be used to ensure the safety of 
neighborhoods and the protection of communities, in-
cluding the prevention of the intimidation of wit-
nesses of illegal drug distribution and related activi-
ties and the establishment of or support for programs 
that provide protection or assistance to witnesses in 
court proceedings. 
‘‘(3) BEST
PRACTICE
MODELS.—The Director 
shall work with the HIDTAs to develop and maintain 
best practice models to assist State, local, and Tribal 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00126
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
127 
governments in addressing witness safety, relocation, 
financial and housing assistance, or any other serv-
ices related to witness protection or assistance in 
cases of illegal drug distribution and related activi-
ties. The Director shall ensure dissemination of the 
best practice models to each HIDTA. 
‘‘SUBCHAPTER III—DRUG-FREE COMMUNITIES 
SUPPORT PROGRAM 
‘‘§ 1031. Establishment of drug-free communities sup-
port program 
‘‘(a) ESTABLISHMENT.—The Director shall establish a 
program to support communities in the development and 
implementation of comprehensive, long-term plans and pro-
grams to prevent and treat substance use and misuse among 
youth. 
‘‘(b) PROGRAM.—In carrying out the Program, the Di-
rector shall— 
‘‘(1) make and track grants to grant recipients; 
‘‘(2) provide for technical assistance and train-
ing, data collection, and dissemination of information 
on state-of-the-art practices that the Director deter-
mines to be effective in reducing substance use; and 
‘‘(3) provide for the general administration of 
the Program. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00127
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
128 
‘‘(c) ADMINISTRATION.—The Director shall appoint an 
Administrator to carry out the Program. 
‘‘(d) CONTRACTING.—The Director may employ any 
necessary staff and may enter into contracts or agreements 
with national drug control agencies, including interagency 
agreements, to delegate authority for the execution of grants 
and for such other activities necessary to carry out this 
chapter. 
‘‘§ 1032. Program authorization 
‘‘(a) GRANT ELIGIBILITY.—To be eligible to receive an 
initial grant or a renewal grant under this subchapter, a 
coalition shall meet each of the following criteria: 
‘‘(1) APPLICATION.—The coalition shall submit 
an application to the Administrator in accordance 
with section 1033(a)(2). 
‘‘(2) MAJOR SECTOR INVOLVEMENT.— 
‘‘(A) IN GENERAL.—The coalition shall con-
sist of 1 or more representatives of each of the 
following categories: 
‘‘(i) Youth. 
‘‘(ii) Parents. 
‘‘(iii) Businesses. 
‘‘(iv) The media. 
‘‘(v) Schools. 
‘‘(vi) Organizations serving youth. 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00128
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS
129 
‘‘(vii) Law enforcement. 
‘‘(viii) Religious or fraternal organiza-
tions. 
‘‘(ix) Civic and volunteer groups. 
‘‘(x) Health care professionals. 
‘‘(xi) State, local, or tribal govern-
mental agencies with expertise in the field 
of substance use prevention or substance use 
disorders (including, if applicable, the State 
authority with primary authority for sub-
stance use and misuse). 
‘‘(xii) Other organizations involved in 
reducing the prevalence of substance use and 
misuse or substance use disorders. 
‘‘(B) ELECTED OFFICIALS.—If feasible, in 
addition to representatives from the categories 
listed in subparagraph (A), the coalition shall 
have an elected official (or a representative of an 
elected official) from— 
‘‘(i) the Federal Government; and 
‘‘(ii) the government of the appropriate 
State and political subdivision thereof or 
the governing body or an Indian tribe (as 
that term is defined in section 4(e) of the 
VerDate Sep 11 2014 
20:53 Jun 20, 2018
Jkt 079200
PO 00000
Frm 00129
Fmt 6652
Sfmt 6203
E:\BILLS\H5925.RH
H5925
pbinns on DSK79D2C42PROD with BILLS